Modulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study.

Matthias M Engelen Quentin Van ThilloAlbrecht BetrainsIwein GyselinckCaroline P MartensValérie SpalartAnna OckermanCaroline DevooghtJoost WautersJan GunstCarine WoutersChristophe VandenbrieleSteffen RexLaurens LiesenborghsAlexander WilmerPhilippe MeerssemanGreet Van den BergheDieter DauweAnn BelmansMichiel ThomeerTom FivezDieter MesottenDavid RuttensLuc HeytensIlse DapperSebastiaan TuylsBrecht De TavernierPeter Verhamme Thomas Vanasschenull null

Published in: Research and practice in thrombosis and haemostasis (2022)

In hospitalized COVID-19 patients, modulation of thromboinflammation with high-dose aprotinin and LMWH with or without anakinra did not improve outcome in patients with moderate to severe COVID-19.

Keyphrases

sars cov
coronavirus disease
high dose
respiratory syndrome coronavirus
early onset
high intensity
growth factor
drug induced